Moving Beyond Hydroxyurea in Polycythemia Vera
Abdulraheem Yacoub, MD, associate professor of Hematology at the University of Kansas Cancer Center, discusses treatment beyond hydroxyurea in patients with polycythemia vera.<br />
Abdulraheem Yacoub, MD, associate professor of Hematology at the University of Kansas Cancer Center, discusses treatment beyond hydroxyurea in patients with polycythemia vera (PV).
Although hydroxyurea has been the mainstay in the treatment landscape of PV, 30% patients will develop resistance or intolerance to the treatment. Investigators are currently trying to develop options for these patients. One of the options already in the landscape, Yacoub says, is treatment with the JAK 1/2 inhibitor ruxolitinib (Jakafi).
In 2014, ruxolitinib was approved by the FDA for patients with PV who are resistant or intolerant to hydroxyurea, based on findings from the phase III RESPONSE trial. Ruxolitinib has demonstrated efficacy in these patients, as PV is associated with an acquiredJAK2mutation. Data from the RESPONSE trial showed that 21% of patients who received ruxolitinib achieved the primary endpoint of ≥35% reduction in spleen volume at week 32, versus 1% in the standard-therapy group (P
Axatilimab Shows Responses With Tolerable Safety in Recurrent/Refractory cGVHD
December 11th 2023Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.
Read More
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
December 10th 2023In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
